Marinus Pharmaceuticals Raises $20 Million in Series B Financing
Company to Advance Ganaxolone Program for the Treatment of Epilepsy
“We’ve made tremendous strides since our Series A financing, with the completion of two Phase 2a clinical trials for ganaxolone in two separate indications, significant patent applications to protect our intellectual property, and advances on formulations which resulted in novel IP and a strong commercial candidate,” said
The funding will advance the Company’s ganaxolone development program for use as a novel adjunctive agent for the treatment of refractory partial seizures and to explore proof of concept studies in psychiatric indications. Marinus Pharmaceuticals has raised a total of
“The management team brings proven and distinctive expertise in developing CNS therapies,” said
Ganaxolone is a synthetic neurosteroid and derivative of the naturally occurring neuromodulator, allopregnanolone. It is being investigated as a first in class treatment for epilepsy. Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in more than 35 Phase 1 and Phase 2 studies. Early epilepsy studies involved more than 100 patients and generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory forms of epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs).
Marinus has successfully developed several proprietary formulations of ganaxolone.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. Marinus Pharmaceuticals is located in
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With
About Sofinnova Ventures
Founded in 1974, Sofinnova Ventures is a venture capital firm specializing in corporate spin-outs with over
Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. For 20 years, they have taken an active and committed role in the companies in which they invest, and have completed more than 72 mergers and acquisitions and 53 IPOs. With
About Foundation Medical Partners
Foundation Medical Partners is a leading national, independent, healthcare venture capital investment firm. Foundation was formed in 2001 with the vision of bringing together cutting edge life science expertise with deep company-building experience. Foundation specializes in early stage investments in the medical device, biopharmaceutical, and predictive medicine technology sectors. Foundation is an active venture investor, providing leadership, support, and strategic resources at every stage in a company’s development. Foundation Medical Partners invests in ventures that demonstrate the capability to improve the practice of medicine and human health.
For more information, visit www.foundmed.com.
Company Contact Media Contact John Krayacich Shirley Chow Marinus Pharmaceuticals Porter Novelli Life Sciences 203-315-5809 212-601-8308 firstname.lastname@example.org email@example.com
SOURCE Marinus Pharmaceuticals, Inc.